Abstract: An information processing device includes a data structure and a processing portion. The data structure is configured to share design information among a time chart, a flowchart, and a sequence program. The processing portion is configured to process the time chart, the flowchart, and the sequence program such that the time chart, the flowchart, and the sequence program link together, depending on the data structure.

Abstract: The object of the present invention is to provide an absorption enhancer capable of introducing high-molecular weight compounds into cells. The object can be solved by a composition of the present invention comprising a polymer compound having a group represented by the following general formula (1) or the following general formula (2) at a side chain, and a compound to be administered with a molecular weight of 1,000 to 1,200,000. wherein X1 is a residue of neutral amino acid or ?-aminoalkanoic acid in which an end amino group and an end carboxyl group are removed, X2 is a residue of cell-penetrating peptide in which an end amino group and an end carboxyl group are removed, X3 is a hydroxyl group, an amino group, an alkoxyl group having 1 to 4 carbon atoms or a benzyloxy group, a is an integer of 0 to 50, and * denotes a bonding site.

Abstract: The object of the present invention is to provide a technique for promoting membrane permeation of a drug, which is highly versatile and highly safe. The object can be solved by a polymer compound having a molecular weight of 1000 or more, wherein the polymer compound has, at an end of a side chain, one arginine or a basic peptide of chain length of 2 to 6 containing one or more arginine, and comprises a guanidino group of 0.5 to 20 mmol/g, originating from arginine.

Abstract: A polysaccharide derivative has a partial structure represented by Formula (1) below. It is preferable that at least one of the amino acids that constitute X2 in Formula (1) below is a basic amino acid. (In the formula, X1 represents a residue obtained by removing the terminal amino group and the terminal carboxyl group from a neutral amino acid or an ?-aminoalkanoic acid, X2 represents a residue obtained by removing the terminal amino group and the terminal carboxyl group from a membrane-permeable peptide, X3 represents a hydroxyl group, an amino group, an alkoxyl group having 1 to 4 carbon atoms, or a benzyloxy group, a represents a number of 0 or 1, and b represents a number of from 0 to 50.

Abstract: A polymer compound has a group represented by Formula (1) or Formula (2) in a side chain. (In Formula (1), X1 represents a neutral amino acid residue or an ?-aminoalkanoic acid residue, X2 represents a membrane-permeable peptide residue, X3 represents a hydroxyl group, an amino group, an alkoxyl group having 1 to 4 carbon atoms, or a benzyloxy group, and a represents a number of from 1 to 50.) (In Formula (2), X4 represents a neutral amino acid residue or an ?-aminoalkanoic acid residue, X5 represents a membrane-permeable peptide residue, X6 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a benzyl group, an acyl group having 1 to 6 carbon atoms, an arylsulfonyl group, or a carboxyl group, and b represents a number of from 1 to 50.).

Abstract: A polysaccharide derivative has a partial structure represented by Formula (1) below. It is preferable that at least one of the amino acids that constitute X2 in Formula (1) below is a basic amino acid. (In the formula, X1 represents a residue obtained by removing the terminal amino group and the terminal carboxyl group from a neutral amino acid or an ?-aminoalkanoic acid, X2 represents a residue obtained by removing the terminal amino group and the terminal carboxyl group from a membrane-permeable peptide, X3 represents a hydroxyl group, an amino group, an alkoxyl group having 1 to 4 carbon atoms, or a benzyloxy group, a represents a number of 0 or 1, and b represents a number of from 0 to 50.

Abstract: A polymer compound has a group represented by Formula (1) or Formula (2) in a side chain. (In Formula (1), X1 represents a neutral amino acid residue or an ?-aminoalkanoic acid residue, X2 represents a membrane-permeable peptide residue, X3 represents a hydroxyl group, an amino group, an alkoxyl group having 1 to 4 carbon atoms, or a benzyloxy group, and a represents a number of from 1 to 50.) (In Formula (2), X4 represents a neutral amino acid residue or an ?-aminoalkanoic acid residue, X5 represents a membrane-permeable peptide residue, X6 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a benzyl group, an acyl group having 1 to 6 carbon atoms, an arylsulfonyl group, or a carboxyl group, and b represents a number of from 1 to 50.

Abstract: A diagnostic marker is composed of particles that have a diameter of from 1 nm to 100 ?m, the particles possessing on their surfaces a site that has a high specific bonding ability to a specific antigen residing on the mucosa of digestive cancers and a site that has a low bonding ability to the mucosa of digestive organs, and further incorporating an identification material.

Abstract: A diagnostic marker is composed of particles that have a diameter of from 1 nm to 100 ?m, the particles possessing on their surfaces a site that has a high specific bonding ability to a specific antigen residing on the mucosa of digestive cancers and a site that has a low bonding ability to the mucosa of digestive organs, and further incorporating an identification material.

Abstract: Provided is an enteric-coated preparation comprising an enteric coating material capable of delivering a drug to a site within the small intestine in a site-specific manner. More specifically, provided is an enteric-coated preparation for delivering a drug to a site within the small intestine in a site-specific manner, comprising a drug-containing preparation and an enteric coating material which covers the preparation, wherein, in Dissolution Test as specified in the Japanese Pharmacopoeia Fourteenth Edition, no dissolution of the drug is observed in the Japanese Pharmacopoeia first fluid (pH 1.2) while dissolution of the drug is observed in the Japanese Pharmacopoeia second liquid (pH 6.8) 20 minutes or later from start of the Dissolution Test. The enteric coating material is preferably selected from the group consisting of hydroxypropylmethyl cellulose acetate succinate, hydroxypropylmethyl cellulose phthalate, methacrylic acid copolymer and carboxymethylethyl cellulose.

Abstract: An oil passageway 102 for suppling oil to a torque converter 30 having a pump impeller, a turbine runner and a stator 33, or removing it therefrom is formed between the shaft member 41 of a stator shaft 40 and the boss portion 42a of its flange member 42 and extends along a transmission input shaft 20, while a pump impeller boss member 31a has an outer periphery supported facing the pump impeller boss member 31a and situated closer to the stator 33 than that portion of the pump impeller boss member 31a which is supported by the bearing and the oil passageway 102 has its openings 40b and 40c situated closer to the stator 33 than that portion of the pump impeller boss member 31a which is supported by the bearing.

Abstract: The present invention is directed to particulate carriers useful as drug carriers in a drug delivery system (DDS) and to pharmaceutical compositions making use of such carriers. The invention is characterized by the use, as the particulate carrier, of: graft copolymer (A) whose graft chain is poly N-alkylacrylamide chain, poly N-alkylmethacrylamide chain, etc.; and a composition containing a combination of the graft copolymer (A) and at least one graft copolymers selected from the group consisting of graft copolymers (B-1) having polyacrylic acid or polymethacrylic acid as the graft chain and graft copolymers (B-2) having a polyvinyl amine compound as the graft chain.

Abstract: An oil passageway 102 for supplying oil to a torque converter 30 having a pump impeller, a turbine rubber and a stator 33, or removing it therefrom is formed between the shaft member 41 of a stator shaft 40 and the boss portion 42a of its flange member 42 and extends along a transmission input shaft 20, while a pump impeller boss member 31a has an outer periphery supported rotatably by a bearing 12. The boss portion 42a of the flange member 42 has its end facing the pump impeller boss member 31a and situated closer to the stator 33 than that portion of the pump impeller boss member 31a which is supported by the bearing is situated, and the oil passageway 102 has its openings 40b and 40c situated closer to the stator 33 than that portion of the pump impeller boss member 31a which is supported by the bearing is.

Abstract: The present invention is directed to particulate carriers useful as drug carries in a drug delivery system (DDS) and to pharmaceutical compositions making use of such carriers. The invention is characterized by the use, as the particulate carrier, of: graft copolymer (A) whose graft chain is poly N-alkylacrylamide chain, poly N-alkylmethacrylamide chain, etc.; and composition containing a combination of the graft copolymer (A) and at least one graft copolymer selected from the group consisting of graft copolymers (B-1) having polyacrylic acid or polymethacrylic acid as the graft chain and graft copolymers (B-2) having a polyvinyl amine compound as the graft chain.

Abstract: A dog clutch mechanism for use as a clutch for switching drive power in a four-wheel-drive vehicle has a case, first and second rotatable shafts rotatably supported coaxially in the case for transmitting a relative torque between front and rear wheels of the vehicle, and a dog clutch comprising a dog piece having first dog teeth and fixedly mounted on the first rotatably shaft and a hub having second dog teeth capable of axially meshing with the first dog teeth and axially slidably mounted on the second rotatable shaft. The dog clutch is selectively engageable for transmitting the relative torque between the first and second rotatable shafts. The first and second dog teeth having respective meshing tapered surfaces for producing thrust forces acting on the hub and tending to move the hub in a direction away from the dog piece when the vehicle is braked while a relative forward torque is being transmitted between the first and second rotatable shafts through the dog clutch.